Luis Palomero

Mr. Luis Palomero

Jaume I University, Castelló de la Plana, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CRCecilia Roux
Cecilia Roux
SJSoode Moghadas Jafari
Soode Moghadas Jafari
RSRahul Shinde
Rahul Shinde
GDGordon Duncan
Gordon Duncan
DCDavid W. Cescon
David W. Cescon
CGChiara Gorrini
Chiara Gorrini
Significance: Immunotherapies targeting the programmed death-1 (PD-1) and its ligand PD-L1 have recently been combined with standard chemotherapy to potentiate the treatment of solid tumors, including triple negative breast cancer (TNBC). Reactive oxygen species (ROS) have been directly linked to the cytotoxic effects of chemotherapy. Here we report that ROS induced either by chemotherapy (paclitaxel) or antioxidant depletion induce PD-L1 expression in macrophages. PD-L1 positive macrophages have immune-suppressive and angiogenic properties that interfere with the efficacy of paclitaxel in vivo. Indeed, PD-L1 blockade reverts this effect and synergizes with paclitaxel to reduce tumor growth. Our work reveals a pathway that further supports the importance of combining taxane and PD-L1 inhibitors as promising anticancer strategy in TNBC.

7 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKShawn P. Kubli
Shawn P. Kubli
CBChristian Bassi
Christian Bassi
CRCecilia Roux
Cecilia Roux
AWAndrew Wakeham
Andrew Wakeham
CGChristoph Göbl
Christoph Göbl
CGChiara Gorrini
Chiara Gorrini
Significance: Basal-like/BRCA1-associated breast cancer (BC) is a very aggressive form of BC that frequently occurs in young women, with devastating effects. Since tailored therapies are lacking for this type of tumor, scientists and clinicians are searching for weaknesses that can be therapeutically exploited. Here we describe the role of the transcription factor aryl hydrocarbon receptor (AhR) in supporting BC growth by controlling reactive oxygen species (ROS) levels and the tumor-promoting features of the microenvironment. In BC cells, AhR activation mediates the link between intracellular ROS regulation and the protumorigenic functions of the surrounding immune system. We propose that tailored inhibition of AhR-regulated pathways can lead to BC eradication by pushing it beyond its ROS tolerance limit and depriving it of tumor-supporting immune cells.

5 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAlvaro Aytes
Alvaro Aytes
AGArianna Giacobbe
Arianna Giacobbe
AMAntonina Mitrofanova
Antonina Mitrofanova
KRKatia Ruggero
Katia Ruggero
JCJoanna Cyrta
Joanna Cyrta
CACory Abate-Shen
Cory Abate-Shen
Deciphering cell-intrinsic mechanisms of metastasis progression in vivo is essential to identify novel therapeutic approaches. Here we elucidate cell-intrinsic drivers of metastatic prostate cancer progression through analyses of genetically engineered mouse models (GEMM) and correlative studies of human prostate cancer. Expression profiling of lineage-marked cells from mouse primary tumors and metastases defines a signature of de novo metastatic progression. Cross-species master regulator analyses comparing this mouse signature with a comparable human signature identifies conserved drivers of metastatic progression with demonstrable clinical and functional relevance. In particular, nuclear receptor binding SET Domain Protein 2 ( NSD2 ) is robustly expressed in lethal prostate cancer in humans, while its silencing inhibits metastasis of mouse allografts in vivo. We propose that cross-species analysis can elucidate mechanisms of metastasis progression, thus providing potential additional therapeutic opportunities for treatment of lethal prostate cancer.

1 December 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QI LiuQI Liu
QI Liu
LMLin Ma
Lin Ma
TJTrevor Jones
Trevor Jones
LPLuis Palomero
Luis Palomero
MPMiquel Angel Pujana
Miquel Angel Pujana
MBMary Helen Barcellos-Hoff
Mary Helen Barcellos-Hoff
Purpose: Following cytotoxic therapy, 70% of patients with human papillomavirus (HPV)-positive oropharyngeal head and neck squamous cell carcinoma (HNSCC) are alive at 5 years compared with 30% of those with similar HPV-negative cancer. Loss of TGFβ signaling is a poorly studied consequence of HPV that could contribute to patient outcome by compromising DNA repair. Experimental Design: Human HNSCC cell lines (n = 9), patient-derived xenografts (n = 9), tissue microarray (n = 194), TCGA expression data (n = 279), and primary tumor specimens (n = 10) were used to define the relationship between TGFβ competency, response to DNA damage, and type of DNA repair. Results: Analysis of HNSCC specimens in situ and in vitro showed that HPV associated with loss of TGFβ signaling that increased response to radiation or cisplatin. TGFβ suppressed miR-182, which inhibited both BRCA1, necessary for homologous recombination repair (HRR), and FOXO3, required for ATM kinase activity. TGFβ signaling blockade by either HPV or inhibitors released miR182 control, compromised HRR and increased response to PARP inhibition. Antagonizing miR-182 rescued the HRR deficit in HPV-positive cells. Loss of TGFβ signaling unexpectedly increased repair by error prone, alternative end-joining (alt-EJ). Conclusions: HPV-positive HNSCC cells are unresponsive to TGFβ. Abrogated TGFβ signaling compromises repair by HRR and increases reliance on alt-EJ, which provides a mechanistic basis for sensitivity to PARP inhibitors. The effect of HPV in HNSCC provides critical validation of TGFβ’s role in DNA repair proficiency and further raises the translational potential of TGFβ inhibitors in cancer therapy.

14 June 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LCLaura Costas
Laura Costas
JFJon Frias‐Gomez
Jon Frias‐Gomez
MGMagdalena Guardiola
Magdalena Guardiola
YBYolanda Benavente
Yolanda Benavente
MPMarta Pineda
Marta Pineda
OTon behalf of the Screenwide Team
on behalf of the Screenwide Team

1 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
PPParasvi S. Patel
Parasvi S. Patel
KAKaran Joshua Abraham
Karan Joshua Abraham
KGKiran Kumar Naidu Guturi
Kiran Kumar Naidu Guturi
MHMarie-Jo Halaby
Marie-Jo Halaby
ZKZahra Khan
Zahra Khan
RHRazqallah Hakem
Razqallah Hakem
Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes considerably increase breast and ovarian cancer risk. Given that tumors with these mutations have elevated genomic instability, they exhibit relative vulnerability to certain chemotherapies and targeted treatments based on poly (ADP-ribose) polymerase (PARP) inhibition. However, the molecular mechanisms that influence cancer risk and therapeutic benefit or resistance remain only partially understood. BRCA1 and BRCA2 have also been implicated in the suppression of R-loops, triple-stranded nucleic acid structures composed of a DNA:RNA hybrid and a displaced ssDNA strand. Here, we report that loss of RNF168, an E3 ubiquitin ligase and DNA double-strand break (DSB) responder, remarkably protected Brca1-mutant mice against mammary tumorigenesis. We demonstrate that RNF168 deficiency resulted in accumulation of R-loops in BRCA1/2-mutant breast and ovarian cancer cells, leading to DSBs, senescence, and subsequent cell death. Using interactome assays, we identified RNF168 interaction with DHX9, a helicase involved in the resolution and removal of R-loops. Mechanistically, RNF168 directly ubiquitylated DHX9 to facilitate its recruitment to R-loop–prone genomic loci. Consequently, loss of RNF168 impaired DHX9 recruitment to R-loops, thereby abrogating its ability to resolve R-loops. The data presented in this study highlight a dependence of BRCA1/2-defective tumors on factors that suppress R-loops and reveal a fundamental RNF168-mediated molecular mechanism that governs cancer development and vulnerability.